Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation for Sensorineural Hearing Loss

What this Trial Is About

Researchers are studying sensorineural hearing loss in patients receiving cochlear implants. The study aims to reduce fibrosis, a common issue that decreases implant effectiveness over time and increases power use. This research evaluates the use of autologous platelet-rich fibrin for its anti-inflammatory effects to slow down the fibrotic process. During cochlear implant surgery under general anesthesia, platelet-rich fibrin prepared by the i-prf technique is applied locally to the round window of the middle ear. After making a postauricular incision and mastoidectomy to access the middle ear, the implant electrode is inserted, and the entry points are covered with fascia. The intervention involves administering platelet-rich fibrin during the routine implant procedure. Participants will have their electrode impedance and neural response telemetry measured during surgery and again at 1 week, 1 month, 3 months, and 6 months after surgery using the Custom Sound EP 5.0 program. These assessments monitor implant function and fibrosis effects. The total study monitoring lasts for six months post-operation.

Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation